Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism

Anwaar, I. ; Gottsäter, A. LU ; Eriksson, K. F. LU ; Jacobsson, L. ; Lindgärde, F. LU and Mattiasson, I. LU (2000) In Diabetes Research and Clinical Practice 50(2). p.127-136
Abstract

Plasma endothelin-1, the nitric oxide (NO) mediator intraplatelet cyclic guanosine monophosphate (cGMP), the prostacyclin mediator cyclic adenosine monophosphate (cAMP) and the macrophage derived inflammatory mediator plasma neopterin were measured in men with Type 2 diabetes mellitus (n = 91), impaired glucose tolerance (IGT; n = 51), previously abnormal glucose tolerance (PAGT; n = 20), and 34 healthy control men. Plasma endothelin-1 was higher in men with Type 2 diabetes mellitus than in controls [4.1 (1.0-14.3) vs. 2.1 (0.2-8.7) ng/l; P < 0.001). Intraplatelet cGMP was higher in men with PAGT [0.84 (0.57-2.76) pmol/109 platelets; P < 0.05], IGT [0.85 (0.48-3.53); P < 0.001] and Type 2 diabetes mellitus [0.90... (More)

Plasma endothelin-1, the nitric oxide (NO) mediator intraplatelet cyclic guanosine monophosphate (cGMP), the prostacyclin mediator cyclic adenosine monophosphate (cAMP) and the macrophage derived inflammatory mediator plasma neopterin were measured in men with Type 2 diabetes mellitus (n = 91), impaired glucose tolerance (IGT; n = 51), previously abnormal glucose tolerance (PAGT; n = 20), and 34 healthy control men. Plasma endothelin-1 was higher in men with Type 2 diabetes mellitus than in controls [4.1 (1.0-14.3) vs. 2.1 (0.2-8.7) ng/l; P < 0.001). Intraplatelet cGMP was higher in men with PAGT [0.84 (0.57-2.76) pmol/109 platelets; P < 0.05], IGT [0.85 (0.48-3.53); P < 0.001] and Type 2 diabetes mellitus [0.90 (0.47-3.86); P < 0.001] than in controls [0.70 (0.42-1.70]. No differences existed between groups concerning intraplatelet cAMP or plasma neopterin. Plasma endothelin-1 correlated with fasting plasma glucose (r = 0.33; P < 0.001) and HbA1(c) (r = 0.29; P < 0.001). In conclusion, elevated plasma endothelin-1 in Type 2 diabetes mellitus and its relationship to glucose and HbA1(c) suggest a putative role for endothelin-1 in diabetic endothelial cell damage. Increased cGMP indicating enhanced production/activity of NO suggests that factors other than reduced NO activity contribute to enhanced platelet aggregation in diabetes. (C) 2000 Elsevier Science Ireland Ltd.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cGMP, Endothelin-1, IGT, Neopterin, Type 2 diabetes
in
Diabetes Research and Clinical Practice
volume
50
issue
2
pages
127 - 136
publisher
Elsevier
external identifiers
  • scopus:0342521474
  • pmid:10960723
ISSN
0168-8227
DOI
10.1016/S0168-8227(00)00190-X
language
English
LU publication?
yes
id
cb0de5d1-e477-475c-81dc-5f4097a65e49
date added to LUP
2020-12-11 14:22:01
date last changed
2025-01-11 01:29:59
@article{cb0de5d1-e477-475c-81dc-5f4097a65e49,
  abstract     = {{<p>Plasma endothelin-1, the nitric oxide (NO) mediator intraplatelet cyclic guanosine monophosphate (cGMP), the prostacyclin mediator cyclic adenosine monophosphate (cAMP) and the macrophage derived inflammatory mediator plasma neopterin were measured in men with Type 2 diabetes mellitus (n = 91), impaired glucose tolerance (IGT; n = 51), previously abnormal glucose tolerance (PAGT; n = 20), and 34 healthy control men. Plasma endothelin-1 was higher in men with Type 2 diabetes mellitus than in controls [4.1 (1.0-14.3) vs. 2.1 (0.2-8.7) ng/l; P &lt; 0.001). Intraplatelet cGMP was higher in men with PAGT [0.84 (0.57-2.76) pmol/10<sup>9</sup> platelets; P &lt; 0.05], IGT [0.85 (0.48-3.53); P &lt; 0.001] and Type 2 diabetes mellitus [0.90 (0.47-3.86); P &lt; 0.001] than in controls [0.70 (0.42-1.70]. No differences existed between groups concerning intraplatelet cAMP or plasma neopterin. Plasma endothelin-1 correlated with fasting plasma glucose (r = 0.33; P &lt; 0.001) and HbA1(c) (r = 0.29; P &lt; 0.001). In conclusion, elevated plasma endothelin-1 in Type 2 diabetes mellitus and its relationship to glucose and HbA1(c) suggest a putative role for endothelin-1 in diabetic endothelial cell damage. Increased cGMP indicating enhanced production/activity of NO suggests that factors other than reduced NO activity contribute to enhanced platelet aggregation in diabetes. (C) 2000 Elsevier Science Ireland Ltd.</p>}},
  author       = {{Anwaar, I. and Gottsäter, A. and Eriksson, K. F. and Jacobsson, L. and Lindgärde, F. and Mattiasson, I.}},
  issn         = {{0168-8227}},
  keywords     = {{cGMP; Endothelin-1; IGT; Neopterin; Type 2 diabetes}},
  language     = {{eng}},
  month        = {{10}},
  number       = {{2}},
  pages        = {{127--136}},
  publisher    = {{Elsevier}},
  series       = {{Diabetes Research and Clinical Practice}},
  title        = {{Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism}},
  url          = {{http://dx.doi.org/10.1016/S0168-8227(00)00190-X}},
  doi          = {{10.1016/S0168-8227(00)00190-X}},
  volume       = {{50}},
  year         = {{2000}},
}